Eagle Pharmaceuticals, Inc. (EGRX): Price and Financial Metrics

Eagle Pharmaceuticals, Inc. (EGRX): $6.48

0.62 (+10.58%)

POWR Rating

Component Grades








Add EGRX to Watchlist
Sign Up

EGRX Price/Volume Stats

Current price $6.48 52-week high $32.44
Prev. close $5.86 52-week low $4.10
Day low $5.87 Volume 188,300
Day high $6.81 Avg. volume 281,536
50-day MA $5.34 Dividend yield N/A
200-day MA $13.08 Market Cap 84.16M

EGRX Stock Price Chart Interactive Chart >


  • Value is the dimension where EGRX ranks best; there it ranks ahead of 99.81% of US stocks.
  • The strongest trend for EGRX is in Quality, which has been heading down over the past 26 weeks.
  • EGRX ranks lowest in Momentum; there it ranks in the 10th percentile.

EGRX Stock Summary

  • EGRX's current price/earnings ratio is 5.68, which is higher than only 6.2% of US stocks with positive earnings.
  • With a price/sales ratio of 0.26, EAGLE PHARMACEUTICALS INC has a higher such ratio than merely 8% of stocks in our set.
  • In terms of volatility of its share price, EGRX is more volatile than 90.62% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to EAGLE PHARMACEUTICALS INC, a group of peers worth examining would be NVVE, IDN, HRMY, ANIK, and PRCT.
  • EGRX's SEC filings can be seen here. And to visit EAGLE PHARMACEUTICALS INC's official web site, go to www.eagleus.com.

EGRX Valuation Summary

  • In comparison to the median Healthcare stock, EGRX's price/earnings ratio is 80.45% lower, now standing at 5.7.
  • EGRX's price/earnings ratio has moved up 22 over the prior 120 months.

Below are key valuation metrics over time for EGRX.

Stock Date P/S P/B P/E EV/EBIT
EGRX 2023-12-29 0.3 0.3 5.7 3.5
EGRX 2023-12-28 0.3 0.3 5.9 3.5
EGRX 2023-12-27 0.3 0.3 5.6 3.5
EGRX 2023-12-26 0.3 0.3 5.7 3.5
EGRX 2023-12-22 0.3 0.3 5.4 3.4
EGRX 2023-12-21 0.3 0.3 5.4 3.4

EGRX Growth Metrics

    Its 3 year net income to common stockholders growth rate is now at -6.3%.
  • Its 2 year price growth rate is now at -21.29%.
  • Its 2 year revenue growth rate is now at 28.13%.
Over the past 67 months, EGRX's revenue has gone up $61,546,000.

The table below shows EGRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 298.231 21.225 21.281
2022-06-30 272.183 35.529 22.79
2022-03-31 246.171 1.13 35.852
2021-12-31 171.546 28.219 -8.627
2021-09-30 179.142 39.898 5.626
2021-06-30 189.217 44.458 18.307

EGRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • EGRX has a Quality Grade of B, ranking ahead of 92.42% of graded US stocks.
  • EGRX's asset turnover comes in at 0.738 -- ranking 36th of 682 Pharmaceutical Products stocks.
  • ACUR, XENE, and KMPH are the stocks whose asset turnover ratios are most correlated with EGRX.

The table below shows EGRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.738 0.756 0.315
2021-03-31 0.719 0.735 0.316
2020-12-31 0.671 0.758 0.264
2020-09-30 0.664 0.761 0.184
2020-06-30 0.628 0.732 0.068
2020-03-31 0.677 0.711 0.109

EGRX Price Target

For more insight on analysts targets of EGRX, see our EGRX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $48.50 Average Broker Recommendation 1.67 (Moderate Buy)

Eagle Pharmaceuticals, Inc. (EGRX) Company Bio

Eagle Pharmaceuticals focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company was founded in 2007 and is based in Woodcliff Lake, New Jersey.

EGRX Latest News Stream

Event/Time News Detail
Loading, please wait...

EGRX Latest Social Stream

Loading social stream, please wait...

View Full EGRX Social Stream

Latest EGRX News From Around the Web

Below are the latest news stories about EAGLE PHARMACEUTICALS INC that investors may wish to consider to help them evaluate EGRX as an investment opportunity.

Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City

Barhemsys Barhemsys -- BARHEMSYS® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration (“FDA”) for rescue treatment of postoperative nausea and vomiting (“PONV”) despite prophylaxis1 and is also approved for the treatment of PONV in patients who have not received prophylaxis and for the prevention of PONV -- -- In patients who experience PONV, the incidence of nausea is substantially greater than the incidence of vomiting2,3 -- -- This post-h

Yahoo | December 6, 2023

Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q

WOODCLIFF LAKE, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on November 27, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not currently in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which requires timely filing of all required periodic financia

Yahoo | November 29, 2023

Eagle Pharmaceuticals Announces Management Change

– CEO and Founder Scott Tarriff Retires – – Chairman Michael Graves to Serve as Interim Executive Chairman – WOODCLIFF LAKE, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced a change in management. Effective immediately Scott Tarriff, Founder, President and Chief Executive Officer of the Company, has announced his resignation and retirement from his positions with the Company as President, Chief Executive Officer and Di

Yahoo | November 29, 2023

Down -33.75% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround

Eagle Pharmaceuticals (EGRX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Yahoo | November 27, 2023

Down -26.73% in 4 Weeks, Here's Why Eagle Pharmaceuticals (EGRX) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Eagle Pharmaceuticals (EGRX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Yahoo | November 10, 2023

Read More 'EGRX' Stories Here

EGRX Price Returns

1-mo 6.58%
3-mo 8.91%
6-mo N/A
1-year -76.03%
3-year -83.93%
5-year -86.79%
YTD 23.90%
2023 -82.11%
2022 -42.60%
2021 9.34%
2020 -22.49%
2019 49.12%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!